Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Dharmalingam M, Aravind SR, Thacker H, Paramesh S, Mohan B, Chawla M, Asirvatham A, Goyal R, Shembalkar J, Balamurugan R, Kadam P, Alva H, Kodgule R, Tandon M, Vaidyanathan S, Pendse A, Gaikwad R, Katare S, Suryawanshi S, Barkate H. Dharmalingam M, et al. Among authors: chawla m. Drugs. 2020 Apr;80(6):587-600. doi: 10.1007/s40265-020-01285-0. Drugs. 2020. PMID: 32162274 Free PMC article. Clinical Trial.
Recommendations for in-clinic PoCT for diabetes management in India.
Saboo B, Sadikot S, Prasanna Kumar KM, Joshi S, Aravind SR, Makkar BM, Chawla R, Kesavadev J, Chawla M, Kovil R, Shah T, Mohit M, Vyas C, Dhandhania VK. Saboo B, et al. Among authors: chawla r, chawla m. Diabetes Metab Syndr. 2019 Jan-Feb;13(1):5-7. doi: 10.1016/j.dsx.2018.05.005. Epub 2018 May 8. Diabetes Metab Syndr. 2019. PMID: 30641753
Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study.
Ajmani AK, Agrawal A, Prasad BLN, Basu I, Shembalkar J, Manikanth N, Subrahmanyam KAV, Srinivasa M, Chawla M, Srivastava MK, Jebasingh F, Achappa B, Agrawal RP, Pulichikkat RK, Meena R, Bhatia S, Gupta SK, Dange A, Srivastava A, Trailokya A, Shahavi V, Shende S. Ajmani AK, et al. Among authors: chawla m. Diabetes Res Clin Pract. 2019 Nov;157:107860. doi: 10.1016/j.diabres.2019.107860. Epub 2019 Sep 14. Diabetes Res Clin Pract. 2019. PMID: 31526825 Clinical Trial.
Sodium-glucose Cotransporter-2 Inhibitors in Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus: A Meta-analysis.
Kovil R, Chawla M, Shah T, Sahoo A, Makkar B, Kesavadev J, Seshadri K, Tiwaskar M, Rajput R, Phatak S, Majumdar S, Gupta S. Kovil R, et al. Among authors: chawla m. J Assoc Physicians India. 2022 Aug;70(8):11-12. doi: 10.5005/japi-11001-0076. J Assoc Physicians India. 2022. PMID: 36082726
318 results